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1 Executive summary
1.1 Background
This report follows publication of the results of the 2006/07 service
reviews on harm reduction carried out by the National Treatment
Agency for Substance Misuse (NTA) and the Healthcare
Commission, two government bodies operating across England.
The aim of this report is to highlight good practice in harm
reduction, based on interviews with local drug partnerships that
performed well in the reviews to identify good practice in
interventions to reduce drug-related harm related to blood-borne
virus and overdose.
1.1.1 Service reviews
Service reviews are designed to assess local drug services and
systems against national standards. During 2006/07, the second
of three service reviews assessed the performance of 149 local
drug partnerships on two key areas – commissioning of treatment
and harm reduction services. This report relates to the findings of
the latter. A similar report relating to commissioning will be
published soon.
1.1.2 Measuring harm reduction
Ten criteria were developed for service reviews. Six focused on
commissioning and four on harm reduction. Each criterion was
scored on the basis of several questions and each local drug
partnership received a score based on these totals (up to a
maximum of 40) and an overall score (from 1–4). 
1.1.3 Interviewing high-scoring partnerships
Partnerships that scored highly on harm reduction were
interviewed to find out about their strategies and practices, to
determine what lessons could be learnt. Several types of drug
partnerships (such as urban and rural) and a variety of staff were
interviewed, in order to identify a number of common themes that
the partnerships believed contributed towards good practice.
1.2 Key factors influencing good 
practice in harm reduction
1.2.1 Harm reduction embedded in the system
• Most local drug partnerships had harm reduction strategies
that were developed and implemented by local expert groups
• Partnerships reported that the availability of good-quality local
data was essential to assess the needs of their populations
• Many partnerships recognised that access to good drug
treatment was essential to harm reduction, which in turn
forms an integral part of a client’s care plan
• Harm reduction was specified as a standard in all contracts
with drug treatment providers, to ensure harm reduction was
delivered by these services
• Almost all of the partnerships interviewed used a variety of
funding sources for harm reduction services
• The involvement of service users in the planning, delivery and
development of harm reduction services was seen as
important. Many partnerships used forums and other
feedback mechanisms as a check on the quality of the
services provided
• The interviewed partnerships described a range of
interventions that were delivered across local drug treatment
systems, including assessment, healthcare, needle exchange,
blood-borne virus testing and treatment pathways, and
services for steroid users.
1.2.2 Prompt and flexible access 
Making access to harm reduction services as easy as possible for
clients was achieved in the interviewed partnerships through:
• Good coverage of specialist harm reduction services and
pharmacies across the partnership area
• Specialist harm reduction services and pharmacies being
open outside office hours
• Outreach services, such as vans and satellite clinics, to reach
clients outside the treatment system
• Delivering a range of interventions in pharmacies, including:
– Distributing injecting equipment and other injecting
paraphernalia
– Pharmacy staff referring clients to appropriate specialist
harm reduction services 
– Drugs workers working in pharmacies to provide brief
harm reduction interventions. 
• All partnerships placed a high priority on testing for blood-
borne viruses, with most aiming to test as many clients as
possible and address blood-borne virus issues at initial
assessment
• Most partnerships reported offering hepatitis A and B
vaccinations to clients attending drug services. Vaccinations
were usually carried out by nurses in specialist harm reduction
services or other drug treatment services
• Hepatitis C treatment pathways were established in most of
the areas interviewed, although all thought these could be
improved. Methods found to help client engagement in
hepatitis treatment included:
– Staff or volunteers accompanying clients to hospital
appointments
4
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– Some partnerships were bringing hepatitis treatment
back into community services to improve access.
1.2.3 Action to reduce deaths from overdose
• Most of the partnerships interviewed had a strategy for
reducing drug-related overdose deaths, usually as part of the
harm reduction strategy. Some partnerships had joined up
with neighbouring partnerships to have a wider strategic focus
• All of the partnerships provided overdose training for service
users and carers 
• Some areas had established enquiry processes for drug-
related deaths and other areas were in the process of
developing these
• The enquiry processes for drug-related deaths were reported
to be more effective if there were good links with the coroner’s
office
• Most partnerships had plans in place to minimise the
overdose risk for those leaving prison in their areas
• Many areas had done proactive work on drug-related death
prevention, mainly through locally targeted campaigns.
1.2.4 Competent staff
• Harm reduction training was standard for all drug treatment
staff
• The harm reduction competences of non-drug treatment staff
working with drug users was also addressed through multi-
agency training
• Most areas had training programmes for pharmacy staff in
contact with drug users to improve their skills and knowledge.
1.2.5 Other factors
• All the partnerships employed staff in co-ordination roles to
co-ordinate harm reduction services
• To achieve high returns of injecting equipment (even as high
as 95–100 per cent), many partnerships had run campaigns
to achieve high returns of injecting equipment
• Where drug litter was an issue, partnerships had identified
hotspots and taken appropriate action, often in conjunction
with the local authority
• Harm reduction interventions were also delivered in non-drug
treatment settings; by criminal justice workers in police
custody suites and housing workers in hostels for example.
2 Background
2.1 The purpose of this report
This report has been produced using the results of the 2006/07
service review on harm reduction carried out by the National
Treatment Agency for Substance Misuse (NTA) and the
Healthcare Commission. Its purpose is to highlight good practice
in harm reduction, based on the local drug partnerships that
performed well in the review and to identify the key factors that
led to these partnerships scoring highly. 
2.2 Focusing on harm reduction
The term harm reduction, as used in this report, is based on the
description of harm reduction in Reducing Drug-Related Harm:
An Action Plan (DH & NTA, 2007):
Harm reduction combines work aimed directly at reducing
the number of drugrelated deaths and bloodborne virus
infections, with wider goals of preventing drug misuse and
of encouraging stabilisation in treatment and support for
abstinence. Providing effective substitution treatments and
effective support for abstinence are complementary aims
of such a balanced response.
This report is one of the outputs from Reducing Drug-Related
Harm: An Action Plan, which sets out the broad streams of action
to be taken in England to enhance harm reduction activities within
drug treatment services. The aim of the plan is to limit the number
of drug misusers dying from drug-related causes or contracting
blood-borne virus infections.
Harm reduction was selected as a priority for the 2006/07 NTA
and Healthcare Commission service review because of concerns
about the increasing incidence of blood-borne viruses, which has
been recorded in recent years by the Health Protection Agency
(2007) in its annual Shooting Up reports.
The government target on drug-related deaths was a 20 per cent
reduction by March 2004. For England the baseline figure was
1,480 drug-related deaths and the target was to reduce drug-
related deaths to 1,184 (an overall reduction of 296 deaths).
Although drug-related deaths have gone down in recent years,
government targets have not been met.
2.3 Service reviews
2.3.1 Background
In 2005, the NTA embarked on a three-year programme of
annual service reviews in partnership with the Healthcare
Commission. These reviews are a key element of the NTA’s aim
to enhance the quality, consistency and effectiveness of drug
treatment. 
5
Good practice in harm reduction
GPHR figure added:Good Practice in Harm Reduction 04/11/2008 14:00 Page 5
Good practice in harm reduction
Service reviews are designed to test the performance of drug
treatment provision and commissioning against key indicators.
They provide a benchmark of the quality of drug treatment and
provide information on areas of weakness, against which
improvement can be planned.
Service reviews are based on a standardised approach and
consist of three parts: 
1. Review criteria are developed in consultation with the field
and piloted in some local partnerships and services
2. Assessments are carried out on the unit of assessment,
which are local drug partnerships. The partnerships and
service providers are assessed against an agreed framework
of key criteria
3. Follow-up work is carried out with the minority (about 10–15
per cent) of partnerships and services that have the weakest
assessments, who may require help to develop action plans
to improve performance.
2.3.2 The 2006/07 service review
During 2006/07, the second joint Healthcare Commission and
NTA substance misuse themed service review took place. This
review assessed the performance of 149 local drug partnerships
and focused on two key areas:
• Commissioning and systems management
• The provision of harm reduction services.
Within these two themes, ten criteria were developed that were
indicators of effective commissioning and harm reduction
provision. These criteria were developed in collaboration with a
wide range of professionals (including service providers,
commissioners and other experts) and service users. Forty-five
questions assessed how well local drug partnerships performed
against these criteria. These question scores were then used to
calculate criteria level and overall scores for each local drug
partnership, using the same scale. Each criterion was scored on
a four-point scale from “weak” to “excellent” (1–4). 
2.3.3 Criteria and scoring
There were then criteria developed for the service reviews on
commissioning and harm reduction. Criteria 1–6 focused on
commissioning. Criteria 7–10 were developed to assess harm
reduction interventions and were:
• Criterion 7: Service providers deliver harm reduction
interventions embedded in the whole treatment system
• Criterion 8: Service users have prompt and flexible access to
needle exchange services, vaccination, testing and treatment
for blood-borne viruses
• Criterion 9: Service providers take action to reduce the
number of drug-related deaths
• Criterion 10: Service providers have staff competent to deliver
effective harm reduction services.
Within each criterion, there were a number of questions, which
contributed to the score for that criterion. The questions are set
out in section 3.2.
Each local drug partnership and mental health trust received a
cumulative criteria score (the maximum possible score was 40)
and an overall score (from 1–4). The full national results –
including overall score, total score and the scores for each of the
ten criteria – were published for every local drug partnership area
in England on the Healthcare Commission website
(www.healthcarecommission.org.uk) in May 2008. The harm
reduction results are included in Appendix 4.
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Figure 1: Distribution of scores across partnerships
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2.3.4 Action planning to improve poor performance
When each partnership area was scored (overall and total scores),
the worst performing partnerships (10–15 per cent of the total
number) received additional help to improve the ways they
provided and commissioned drug treatment services, including
assistance with producing a detailed action plan to demonstrate
how they can improve the areas where they were rated as “weak”.
The partnerships produced action plans which were signed off by
the review leads at the NTA and Healthcare Commission, and
shared across both organisation’s regional teams and the strategic
health authority.
The NTA regional teams have used the results of the service
review to inform their work with local drug partnerships, as part of
the treatment planning process. Partnerships have developed
action plans for 2008 in response to the review results and
subsequent improvements. Their performance will continue to be
monitored by the NTA regional teams and regional stakeholders
through quarterly reviews.
2.4 Rationale and methodology for this report
2.4.1 Identifying good performance in harm reduction
In addition to targeting the poorest-performing areas, for the
purposes of this report the NTA identified the areas that scored
highest in the service review, specifically against harm reduction
criteria. From these it was possible to identify potential good
practice and the factors in local treatment systems that
contributed towards making these areas score highly. This was
similar to the rationale used to produce Good Practice in Care
Planning (NTA, 2007a), based on the results of the 2005/06
reviews. The report identified common themes across various
areas that scored highly for care planning in the review and
highlighted these as important factors that contributed to these
partnerships performing well on care planning.
As with the care planning report, the aim was to speak to people
in a number of the high-scoring partnerships, gain information
about their strategies and practices, and determine what lessons
could be learnt. Partnerships that scored well on harm reduction
were selected by examining in detail at the scores across the
individual criteria. This produced a shortlist of partnerships, which
were interviewed to obtain more information on their drug
treatment systems and harm reduction practices (for more
information on these areas, and how they were selected see
Appendix 2). 
2.4.2 Interviewing local drug partnerships
Many types of local drug partnerships were interviewed for this
report; in urban and rural areas, new and well-established
treatment systems, and NHS and third sector providers.
The interviews were conducted with a range of staff in the local
drug treatment systems, including joint commissioning managers,
partnership strategy managers, harm reduction leads, needle
exchange co-ordinators, clinical leads, other clinicians, harm
reduction service managers, and user and carer representatives.
These meetings were arranged in collaboration with the relevant
NTA regional team, involving the NTA deputy regional manager
responsible for covering the particular partnership. All of the
interviews took place with all relevant key staff in a meeting using
a set of questions as the basis for discussion. 
From the interviews, a number of common themes were identified
that were believed by the partnerships to contribute towards
good practice in providing harm reduction services. These
themes are set out in section four. There are also a number of
case studies from specific partnership areas, which have features
and policies that were considered good practice. 
3 Summary of the 2006/07 
service reviews
3.1 Results 
The overall results of the service reviews, which included harm
reduction and commissioning, showed that just over a third (34%)
of partnerships scored “excellent”, almost half (45%) scored
“good”, and just over a fifth (21%) were “fair”. No partnerships or
primary care trusts (PCTs) scored “weak” in this review. The
highest total score by any partnership was 38 (out of a maximum
of 40) and the lowest was 18. Table 1 shows the distribution of
Table 1: Distribution of overall service review ratings across partnerships
Local drug partnerships Primary care trusts
Number Percentage Number Percentage
1. Weak 0 0% 0 0%
2. Fair 31 21% 34 22%
3. Good 67 45% 63 41%
4. Excellent 51 34% 55 36%
Total 149 100% 152 100%
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overall scores and Figure 1 shows the distribution of the total
scores across all partnerships. (Due to rounding up or down, the
percentages may not total 100 per cent.)
The results of the review show that the vast majority of
partnerships were performing within acceptable levels, although
there was room for improvement. Although no partnerships had
an overall score of “weak”, the review revealed that the majority of
partnerships had some deficits in key areas and demonstrated
the need for partnerships to develop targeted action plans to
address the gaps in commissioning practice and the provision of
harm reduction services. 
3.2 Results by harm reduction criteria
As demonstrated in Table 2, the strongest criterion in the review
was action taken to reduce drug-related deaths, with 61 per cent
scoring “excellent” and 18 per cent “good”. Scoring was also
strong on criterion 10 – whether service providers had staff which
were competent to deliver effective harm reduction services. The
weakest criterion was 8, which relates to access to harm
reduction services – over half of partnerships scored “fair” or
“weak” for this criterion. Within this criterion, almost all
partnerships failed to score well on responses to hepatitis. 96%
scored “fair” or “poor” for their testing for hepatitis B and C and
hepatitis B vaccination, and 98 per cent scored “fair” or “poor” on
their response to hepatitis C. A third of partnerships scored “fair”
or “weak” on the criterion of whether or not harm reduction
interventions were embedded in the whole system. 
More information on performance against each question making
up the criteria is set out in section 4.
3.3 Key findings
The key messages and findings from the review, in relation to
harm reduction, were: 
• Vaccination for hepatitis B and testing and treatment for
hepatitis C were not provided widely enough by local drug
treatment systems. Almost all (95.3%) of local drug
partnerships had less than three-quarters (75%) of their
service users being offered a hepatitis B vaccination and
twenty-nine per cent did not have a protocol relating to
hepatitis B. The vast majority (95.3%) of partnerships reported
that less than fifty per cent of their service users had a
recorded test date for hepatitis C. This is a clear national
priority for improvement in the light of the scale of infection
amongst injecting drug users
• In many local drug partnerships, harm reduction interventions
were not provided broadly enough across the treatment
system or sufficiently integrated into it
• Nearly half of service users surveyed thought that the harm
reduction services they received were not comprehensive
enough
• There is a clear deficit nationally in the provision of out-of-
hours needle exchange, with just under half of local drug
partnerships scoring “weak”. Only 21 per cent had most of
their needle exchange services open on Saturday and two
per cent on Sunday
• Community prescribing services were assessed as providing,
in the main, a good range of harm reduction interventions
• While strategic planning for harm reduction services was
generally good, the scale of both preventable and treatable
blood-borne virus infections, and the high rates of overdose
deaths, call for additional action by local drug partnerships
• While local drug partnerships have made significant progress
in developing systems and protocols to reduce the number of
drug-related deaths, more needs to be done to reduce these
drug-related overdoses even further. Only sixty-eight per cent
of local drug partnerships had a multi-agency strategic plan
for reducing the number of drug-related deaths.
The service review provides a helpful national picture of strengths
and weaknesses in harm reduction and commissioning. The
review indicates that progress is being made on vital issues but
there are still a number of areas for improvement. 
Weak Fair Good Excellent
7. Service providers deliver harm reduction interventions
embedded in the whole treatment system
1% 32% 34% 34%
8. Service users have prompt and flexible access to needle
exchange services, vaccination, testing & treatment for BBV
1% 50% 43% 7%
9. Service providers take action to reduce the number of
drug-related deaths
2% 19% 18% 61%
10. Service providers have staff competent to deliver effective
harm reduction services
0% 30% 50% 20%
Table 2: Overall harm reduction results by criteria
Good practice in harm reduction
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The full results of the review can be found in the report Improving
services for substance misuse: Commissioning drug treatment
and harm reduction services (HC & NTA, 2007).
4 Factors influencing 
good performance 
4.1 Introduction
This section presents the findings of the interviews with the high-
scoring partnerships, and links them directly to the criteria and
questions from the service reviews.
4.2 Criterion 7: Harm reduction embedded 
across the treatment system
Criteria question scores are shown in Table 3.
1. Does the local drug partnership have a harm reduction
strategy informed by internal and external data?
2. Did the local needs assessment establish the level of need
for harm reduction interventions?
3. Where are harm reduction interventions provided in the
treatment system?
4. Which harm reduction interventions are provided in
community prescribing services?
5. Do service contracts include harm reduction?
6. How comprehensive are harm reduction interventions as
experienced by service users?
4.2.1 A strategy informed by internal and external data
Having a harm reduction strategy informed by data was an area
that scored well in the service review – two-thirds of partnerships
scored “excellent” or “good”.
Almost all of the partnerships interviewed for this report had a
written harm reduction strategy, which was reflected in most
scoring “excellent”. Most of these strategies had been developed
in the past year or two. The harm reduction strategies had all
been preceded by a needs assessment that had identified the
areas for development. 
For most areas, the harm reduction strategy was developed by a
local expert harm reduction group and overseen by a harm
reduction strategy group, by another type of implementation
group, or by using existing partnership subgroups. These groups
met regularly and fed in through local structures. Partnerships
reported that there was good engagement of key local partners in
these groups and some used action plans to implement harm
reduction strategies.
4.2.2 An assessment to establish the levels of need 
This was another question for which most scored well in the
service review – 78 per cent scored “excellent” or “good”.
All the partnerships interviewed had local needs assessment
processes in place; again, reflected in most of them scoring four.
These needs assessments were managed by the partnerships,
who utilised a range of local data sources and was passed
through local expert groups to analyse and make
recommendations. The quality of the harm reduction needs
assessments was generally believed to be dependent on the
quality of the data available. All the partnerships collected at least
some data on clients using needle exchange services, although
the amount of data collected varied from area to area. Most areas
collected basic information from clients such as their initials,
postcode, drugs used and ethnicity. 
There were also varying degrees of complexity of databases and
data collection systems for harm reduction data. Most areas had
separate databases for pharmacy and specialist needle exchange
activity. A few areas, which had a greater focus on data collection
and use, had a combined (specialist and pharmacy needle
exchange) harm reduction dataset.
At a very basic level, the data from needle exchanges in the
interviewed partnerships was able to show the levels of activity
and numbers of packs distributed from pharmacies, which was
the basis for payment to pharmacies. However, most
partnerships wanted to do more with their needle exchange data
and used it for a variety of strategic purposes, including:
• Monitoring activity in harm reduction services
• Analysing local trends relating to harm reduction services
• Carrying out needs assessments for harm reduction
• Feeding into wider drug treatment needs assessments
• Creating regular reports on harm reduction activity
Q1 Q2 Q3 Q4 Q5 Q6
Weak 25% 15% 15% 23% 11% 21%
Fair 9% 7% 83% 7% 29% 48%
Good 17% 23% 2% 20% 39% 31%
Excellent 50% 55% 0% 49% 21% 0%
Mean 2.9 3.2 1.9 2.9 2.7 2.1
Table 3: Responses to criterion 7 (harm reduction embedded
across the treatment system)
Good practice in harm reduction
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• Correlating with prevalence data – the “Glasgow data” (NTA,
2006b) or other local prevalence data – to check the
penetration of harm reduction interventions into the drug
using population
• Correlating with other relevant local data such as police and
local authority data as well as their NDTMS treatment data
• Obtaining comprehensive records of interventions service
users had received, to enable better assessments and more
targeted interventions 
• Tracking service users through the local treatment system –
this could only be done if the services used a more complex
local harm reduction database.
As well as data on clients in harm reduction services, data on
discarded needles was also collected by most partnerships. This
needle finds data was used to locate local hotspots and target
these accordingly. More information on this issue is in section
4.6.2.
Some partnerships had dedicated research staff to analyse
treatment and harm reduction data.
4.2.3 Where interventions are provided 
Criterion 7 as a whole, which focused on harm reduction being
embedded in the whole treatment system, scored well in the
service review (over two-thirds of partnerships scored “excellent”
or “good”). However, this particular question did not score well at
all, with almost all (98%) partnerships scoring “fair” or “weak”. The
question was asked to find out whether harm reduction
interventions were being provided by services across the local
treatment system (as recommended in Models of Care (NTA,
2006)), and not just being provided in open-access services.
Despite most of the interviewed partnerships scoring “fair”, the
majority of them expressed the importance of good drug
treatment in reducing harm, with the point regularly made that the
most effective form of harm reduction is to keep people in
treatment. In relation to this, some partnerships pointed to high
numbers of people in structured drug treatment as an important
factor in harm reduction. Others mentioned local prescribing
audits, which had showed patients on doses of medication within
current guidelines and this was considered an important harm
reduction measure.
Some of the areas interviewed, which had a long history of
providing drug treatment services, pointed to an established
culture of harm reduction among treatment services and staff
who all saw it as an integral part of all their work. In these areas,
the commissioners also felt that they were part of this culture.
Many of the treatment services in these areas grew out of existing
harm reduction services or were developed by organisations and
trusts that already had experience of doing harm reduction work.
Case study: Bradford harm reduction database
The local drug partnership in Bradford set up a
comprehensive harm reduction database, which has a full
range of information on clients, from pharmacy and specialist
needle exchange services.
Harm reduction services collect a range of client data as well
as asking the client for a password, which enables staff to
identify their records on the database on each visit. Data
collected includes personal client information (e.g. date of
birth, postcode area and ethnicity) and the injecting
equipment and paraphernalia they receive and return.
Recording the client’s drug of choice enables treatment staff
to monitor whether clients are being given the right
equipment. Information recorded on the distribution of
paraphernalia can be used to check if enough is being given
out to reduce the risk of blood-borne viruses.
The database is live, so once the data is uploaded, drug
service staff across the city have access to it. The database
allows client tracking across the local treatment system and
makes a range of information available so clients, reducing the
need for clients to be asked the same questions repeatedly,
as well as prompting staff to current issues relating to that
client, such as vaccination schedules and health problems).
Since it was implemented, staff and clients have reportedly
received the database positively.
Case study: Wigan criminal justice harm reduction services
Wigan has an integrated system of criminal justice and
treatment services, which includes extensive harm reduction
through the criminal justice system. The drug treatment
services work closely with the police though the Tough
Choices project, which due its consultative approach has not
alienated the service user group. 
The Tough Choices staff work in custody suites to initiate
conversations with substance misusing clients about blood-
borne viruses, safer injecting and making them aware of drug
services in the community. The Tough Choices workers also
accompany clients to appointments in the community.
Outreach workers attend drug raids to ensure that punitive
measures are carried out in the most supportive way. For
those people who are not imprisoned, engagement with
services is strongly encouraged. Following imprisonment
individuals are referred to CARATs or DIP.
A good culture of partnership working was reported across
the partnership, which is strengthened by the local area
agreement.
Good practice in harm reduction
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These harm reduction and treatment services had usually been in
place for a long time, allowing a wealth of expertise to build up
among the staff, many of whom had been in their posts for
number of years. Some areas thought that this longevity and
consistency was important, allowing well-established relationships
with clients and promoting the staff’s ability to share their
knowledge and expertise with newer team members.
All the areas interviewed said they recognised that harm reduction
is more than just needle exchange, viewing harm reduction
services as an integral part of the local treatment system, not a
separate adjunct confined to standalone harm reduction services.
These areas all had discrete specialist harm reduction services,
but also emphasised the importance of harm reduction
interventions throughout all the local treatment services in Tiers 2,
3 and 4. Harm reduction was also seen as an integral part of a
client’s care plan, being flagged up at the client’s initial
assessment and always discussed throughout its development.
Some of the treatment services interviewed reported the need to
strike a balance between providing a confidential harm reduction
service to clients and being able to give out needles and injecting
equipment to clients who were already on substitute
prescriptions. They talked about managing potential client unease
around receiving injecting equipment from staff who may also be
involved in their other treatment interventions, or being seen to
attend a needle exchange. Although harm reduction was
considered to be an integral part of the whole drug treatment
system, some partnerships thought that it was important to have
specialist harm reduction services and pharmacy schemes
physically separate from structured drug treatment services.
However, there was always a strong emphasis on very close
working links between these harm reduction agencies and the
treatment agencies, so that there would be easy assessment and
referral into structured treatment if the client desired, and easy
access across treatment and harm reduction agencies for clients
who were already in structured treatment. The importance of
having both specialist standalone harm reduction services and
harm reduction integrated into the treatment system was
continually emphasised.
Interventions which were delivered across local treatment systems
in the interviewed partnerships included the following:
Advice and information
All areas provided a range of harm reduction advice and
information to drug users – both in specialist harm reduction
services and in structured community treatment. This included
basic drug information and advice on safer injecting and overdose
prevention. Some services provided structured training to service
users on safer injecting and overdose. 
Some areas provided telephone helplines for information and
advice. The exact nature of the helplines varied, but they
included: 
• Harm reduction advice for drug users 
• Advice for family and friends
• Info about local harm reduction services
• Help with what to do about discoveries of discarded injection
equipment.
Screening and assessment
It was reported that when clients first make contact with drug
services, their basic details are taken, which usually included the
initials of their name, drugs of use and their injecting history.
Clients were also given a basic healthcare assessment, screening
assessment and triage assessment for entry to structured drug
treatment. The assessment would identify a client’s particular
harm reduction needs and appropriate interventions could be
then offered. 
Healthcare 
Some partnerships made it a priority to ensure that every client
entering drug services for the first time received a general
healthcare screening or assessment. These screenings were
usually carried out by keyworkers, although sometimes the
healthcare assessments were done by harm reduction nurses.
Staff in the drug services also regularly provided interventions
such as checking injecting sites and advising about how to rotate
these sites. Many services also had nurses providing wound care
to service users. 
The partnerships reported that if it was not possible to provide
wound care in the drug treatment or harm reduction service, it
was usually available through referral to local health centres or
hospitals. In some areas, the healthcare needs of drug users
were mainly met in primary care, with specialist nurses running
specific clinics in primary care services. Some areas had begun
projects working with district nurses to provide healthcare
interventions to drug users.
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Needle exchange
All areas interviewed provided a range of needle exchange
services, usually based at either fixed-site harm reduction
services linked to specialist treatment services, or in pharmacies
(often these were also the pharmacies which were involved in
supervised schemes for consumption of prescribed opiates). 
The specialist needle exchange services all provided a wide range
of injecting equipment, giving clients a choice of needles and
syringes and other equipment such as Stericups, filters and citric
acid as well as harm reduction information leaflets. Some also
provided free condoms. The pharmacy needle exchanges mostly
only provided packs, which included needles and syringes and
often a sharps bin to return used works and information leaflets.
However, a few pharmacies had a small amount of individual
syringes for clients to take as extras and some provided packs of
paraphernalia. 
The provision of a range of needle exchange services was
deemed very important by all the partnerships interviewed
because they believed that it was necessary to have a
comprehensive coverage of services and that clients get a choice
of what type of service they use. There was usually a balance of
coverage between specialist needle exchange and pharmacy-
based services. How these were used depended on the areas. In
some places, the specialist services were more popular with
clients, and in other areas the pharmacy services were better
attended. This was due to a number of factors, including location,
historical patterns of service use, and desire for anonymity.
Blood-borne virus testing and treatment pathways
All partnerships reported that they tested clients for blood-borne
viruses, mainly hepatitis B and C. Most areas aimed to test many
clients as possible. They also aimed to provide as many
vaccinations as possible for hepatitis B and provide pathways to
treatment for hepatitis C if the clients tested positive for this virus.
Testing and treatment for blood-borne viruses are covered in
more detail in sections 4.3.5 and 4.3.6.
Harm reduction nurses
All high-performing partnership areas employed harm reduction
nurses to carry out a range of interventions. These nurses were
usually based at the main fixed-site harm reduction service or the
community drug team, although they would often work at satellite
clinics at other locations in the partnership area. They saw clients
on both an appointment (following referral) and drop-in basis.
The harm reduction nurses were responsible for a range of
interventions including:
• Conducting healthcare assessments
• Wound care
• Checking with clients about previous tests and vaccinations 
• Sexual health screening, testing and providing related
information
• Blood-borne virus testing and vaccination – in some areas,
nurses were trained in phlebotomy (if this was not the case,
clients were referred to other health services to have bloods
done)
• Pre- and post-test counselling for blood-borne virus testing
• Referral to other services.
Case study: Knowsley home outreach service
Knowsley provides a home outreach service comprising of
nurses and outreach workers. The service is a partnership
between the Lighthouse Project (the community drug services
provider) and Knowsley PCT. The nurses have a general
nursing background and have experience of working with
drug misusers. The outreach workers and nurses visit clients
in their homes and deliver a range of harm reduction
interventions including blood-borne virus testing, hepatitis B
vaccination, wound care and safer injecting advice.
This outreach serves both to provide interventions to clients
who are unable to attend the fixed-site harm reduction
services, and to encourage people who are resistant to come
into the fixed site services to attend these services in the
future and benefit from the full range of harm reduction
interventions available.
Some partnerships perceived harm reduction as a partnership
venture with primary care and emphasised the necessity of
strong links between drug services and primary care services.
In addition to drug-specific harm reduction services, some
services also gave sexual heath advice and a few services
had links to genitourinary medicine (GUM) clinics.
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Services for steroid users
All partnerships reported that steroid injecting was a problem in
their area, with the majority reporting that it was an issue of rising
importance. Some had seen an exponential rise in steroid use in
recent years, with steroid users responsible for more than half of
needle exchange activity in some services. A number of areas
had developed, or were in the process of developing, services for
steroid users. These included needle exchanges or mobile needle
exchanges in local gyms, outreach and satellite services in gyms,
special steroid clinics at the harm reduction service and the
provision of advice and information to steroid users.
Steroid misuse is not currently within the remit of the NTA,
although non-prescribed anabolic steroids and other performance
and image enhancing drugs are under review as part of the
forthcoming NICE guidance on needle and syringe programmes.
4.2.4 Interventions provided in community 
prescribing services
This question scored reasonably well, with over two-thirds (69%)
of partnerships scoring “excellent” or “good”.
All the partnerships interviewed reported that they provided a
good range of harm reduction interventions within community
prescribing services, which was backed up by their review
scores. These interventions were usually carried out by a
combination of keyworkers and nurses. The majority of the harm
reduction interventions were delivered by drugs workers in the
context of keyworking relationships with their clients. This
included screening and assessments (healthcare assessments
and substance misuse assessment), harm reduction advice and
information, advice about safer injecting and avoiding overdose.
More specialist harm reduction interventions such as testing for
blood-borne viruses, hepatitis B vaccinations and wound care
were done by harm reduction nurses working with the substance
misuse services. 
For more detail on these interventions, see section 4.2.3.
4.2.5 Harm reduction in service contracts
The issue of having harm reduction in service level agreements
was one that scored reasonably in the service review, with 60%
of partnerships scoring “excellent” or “good”. 
Across the partnerships interviewed, the review scores showed a
mixed picture, although all the partnerships reported that harm
reduction was specified as standard in all contracts and service
level agreements with their drug service providers, even to the
extent of having explicit harm reduction statements or clauses to
ensure delivery of harm reduction interventions. This was
standard for all community services commissioned through the
local joint commissioning groups because commissioners wanted
to be sure that harm reduction was being delivered in all
commissioned services, not just those traditionally seen as Tier 2
services.
However even in the high-scoring partnerships interviewed, very
few had specifically required harm reduction in contracts for Tier
4 or abstinence-based services. Most partnerships cited
difficulties in specifying harm reduction in Tier 4 contracts,
particularly residential rehabilitation, due to the ad hoc way these
services were purchased as well as potentially conflicting views
on the importance of harm reduction with some Tier 4 providers.
In addition, most residential rehabilitation was purchased by local
authorities outside of local drug partnership commissioning
arrangements.
Almost all of the partnerships interviewed used a variety of
funding streams for harm reduction services. The majority of the
funding for these services came from the adult pooled treatment
budget (PTB), but most areas also had a substantial contribution
from the PCT, with a few areas having as much as a 50-50 split
between the PTB and PCT or other partner’s funding of harm
reduction services. In these local drug partnership areas, there
was always a strong partnership between the drug treatment
commissioners and their health partners, and the mainstream
health bodies (including public health) were well aware of the
importance of funding harm reduction. 
More widely, there was also plenty evidence of strong working
relationships with other partners in the local drug partnership and
joint commissioning group, with the vast majority of the
interviewed areas also receiving funding for harm reduction
Case study: Harm reduction nurses in Tameside
Tameside runs a nurse-led harm reduction service, which has
two full-time harm reduction nurses based in local treatment
services and working across the local treatment system. 
Partnership representatives reported that having two nurses
enables better access to services, allowing one nurse to run
satellite services and work with primary care services, and the
other to cover the substance misuse service and needle
exchange. This means that there is always usually a nurse
available for drop-in appointments when clients attend the
needle exchange. A full range of harm reduction interventions
are offered, including blood-borne virus testing, vaccination,
and wound care and dressing. 
The harm reduction nurses see clients on both an ad hoc and
appointment basis and run clinics in conjunction with the
doctors’ clinics, so that clients can address a range of issues
together and are able to see the doctor, their keyworker and
the nurse all in one visit. 
The nurses also do home visits, mainly for clients with children
and those who are ill. These visits are done in conjunction
with either the family liaison team or the client’s keyworker.
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services from other DAT partners who were signed up to the
harm reduction agenda and were willing to contribute resources.
This included Drug Interventions Programme (DIP) monies as well
as funding from local authorities (social services and
environmental health), probation and police. 
Many areas talked the advantages of having a strong joint
commissioning group. They reported that a lot of work had been
done with partners to ensure that harm reduction was seen as
everyone’s responsibility.
4.2.6 Service user opinions and involvement
The service review used data from the NTA 2006 user satisfaction
survey (NTA, 2007b) for this question, which showed that over
two-thirds (69%) of partnerships scored “fair” or “weak”.
However, despite these low scores, most of the partnerships
interviewed reported general user satisfaction with their harm
reduction services. Most of these partnerships had mechanisms
in place for regular user consultation and feedback on local drugs
services, including harm reduction services. These usually
included regular meetings between the DAT and user
representatives, feedback from local user groups and forums,
and information provided though advocacy services.
The involvement of service users in the planning and delivery of
harm reduction services was an issue that emerged strongly
across all the partnerships interviewed. Many of these
partnerships stressed the need for service users to be enabled to
become partners in the development of local harm reduction
services and effect change in services. User involvement in local
commissioning structures was reported to be an important part
of this process.
In most of the partnerships interviewed, service users were seen
as natural partners in the planning and delivery of harm reduction
and drug treatment services. Many of the partnerships utilised
service user feedback through forums and individual feedback as
a useful check on the quality of the services being provided. A
number of examples were given of instances when user feedback
had raised awareness of local problems with harm reduction
services and how the partnership was subsequently able to take
quick action to address these service issues. These included
reported negative attitudes of pharmacists, or particular services
not being made available to service users. After this was reported
to the partnership, action was taken to rectify the situation.
There was also evidence that service users had helped to identify
the need for new harm reduction services or staff posts and had
also helped to advise on what materials were given out by needle
exchange services, particularly the contents of needle exchange
packs (for example, the inclusion of citric acid, or a range of
needles).
Other service user and carer initiatives reported in the interviews
included the following, which were funded by the partnerships:
• Regular surveys of service user views by the partnership
• Using service user groups to deliver harm reduction
messages (such as blood-borne virus testing and vaccination)
and to publicise and encourage access to harm reduction
services among their peers
• User-run peer education programmes
• A user-run needle exchange operating on weekends
• Providing training to users, particularly on blood-borne viruses
and overdose.
4.3 Criterion 8: Prompt and flexible access 
to harm reduction services
Results of these questions are shown in Table 4.
1. What proportion of injecting drug users access needle and
syringe exchange services?
Case study: Kirklees user involvement initiatives
Service user consultation was reported to be at the heart of
service development in Kirklees. The partnership has put user
involvement in place across the board in local treatment
system. 
There is an annual user survey, carried out by service users,
through the local user forum. The survey also targets people
who are not currently in drug treatment.
The partnership also uses the local service forums and
advocacy groups to obtain regular feedback on services,
including harm reduction services, and can take action to
remedy any problems. The advocacy service supports and
enables service users to speak out about issues that concern
them. User feedback has been responsible for the
development of new harm reduction services, including the
advocacy service and a mobile needle exchange serving rural
areas.
As well as initiatives, it was often the quality of the
relationships between service users and staff that was
highlighted as one of the most important features of user
involvement. Some partnerships had put a strong emphasis
on the quality of relationships, and working with service
providers to improve them where necessary.
The involvement of carers was also viewed to be an important
aspect of providing good harm reduction services. Some
carer initiatives funded by the partnerships included:
• Overdose training provided to carers
• A carer-run 24-hour telephone helpline 
• Drop-in family support services.
Good practice in harm reduction
GPHR figure added:Good Practice in Harm Reduction 04/11/2008 14:00 Page 14
2. Do dedicated and pharmacy-based needle and syringe
exchange services provide out-of-hours services to service
users?
3. Is harm reduction fully covered in the in the needle exchange
services?
4. What services do pharmacy-based needle and syringe
exchange services offer to needle exchange clients?
5. How many service users have been tested and/or
vaccinated against hepatitis B virus?
6. What is the partnership’s response to hepatitis C and HIV?
4.3.1 Uptake of needle and syringe exchange services
Access to harm reduction was an issue that scored well in the
service review, with almost half (48%) of partnerships scoring
“excellent” on the proportion of injecting drug users accessing
needle exchange schemes in their area. Most of the partnerships
interviewed reported that they had good coverage of harm
reduction services across their areas, enabling easy access for
clients to services. 
The interviewees aimed to make accessing services as easy as
possible for clients. This was achieved in a number of ways. In
addition to out-of-hours service provision (see section 4.3.2),
most partnerships also provided outreach services to engage
with clients who were outside treatment and were unwilling or
found it difficult to access treatment services and fixed-site harm
reduction services.
Outreach services
Despite the extended opening of specialist and pharmacy needle
exchanges, in some areas there were still identified access needs
for particular communities or users. For these areas, outreach
services were provided to meet this need. Outreach is a delivery
mechanism for a range of interventions and services. In the
interviewed partnerships, these services covered four main areas:
• Mobile needle exchange vans, which were not specifically
labelled as needle exchange vans, but focused on providing
general health and drugs information, with needle exchange
facilities available
• Domiciliary interventions, where harm reduction outreach
workers would bring injecting equipment to the homes of
clients. Some services would also provide home visits to
clients to deliver harm reduction interventions, including
blood-borne virus testing and vaccinations
• Detached outreach workers, providing a basic needle
distribution and harm reduction services to clients on the
street
• Satellite clinics – some areas had harm reduction nurses and
drugs workers running satellite clinics in areas which had
limited access to fixed-site services (for example a drop-in
based in a health centre on particular days). 
4.3.2 Out-of-hours provision
This question did not score well in the review with the vast
majority of partnerships (88%) scoring “fair” or “weak” (though a
score of “excellent” was not possible due to the way the scoring
was constructed). The scores for the partnerships interviewed
was a mixed picture, though all reported that there was a good
range of out-of-hours services made available. Out-of-hours
service provision was covered by the following:
Out-of-hours specialist harm reduction services
All of the partnerships had specialist harm reduction services
which opened outside of normal office hours to enable better
client access. Usually this meant having one or two evenings a
week where at least one service was open late (up to 8pm), and
opening on Saturdays (mainly Saturday mornings).
Out-of hours pharmacies providing needle exchange
The issue of out-of-hours opening times was covered in most
areas by pharmacies which opened early and late. The majority of
pharmacies were open outside office hours and there were also
many instances of needle exchanges in 100-hour pharmacies,
and even one in a 24-hour pharmacy. In many areas, the
partnership had strategically ensured coverage by recruiting
pharmacy needle exchange services in parts of the borough or
county that had been shown to have less-easy access to drug
services. Some areas had the pharmacies providing needle
exchange opening late on a rota basis.
Table 4: Responses to criterion 8 (prompt and flexible access to
harm reduction services)
Q1 Q2 Q3 Q4 Q5 Q6
Weak 24% 44% 9% 5% 26% 95%
Fair 14% 44% 4% 9% 70% 3%
Good 14% 12% 28% 30% 0% 1%
Excellent 48% N/A 58% 56% 4% 0%
Mean 2.9 1.7 3.4 3.4 1.8 1.1
15
Good practice in harm reduction
GPHR figure added:Good Practice in Harm Reduction 04/11/2008 14:00 Page 15
16
4.3.3 Harm reduction in needle exchange services
This question scored well in the review with over half (58%) of
partnerships scoring “excellent” and only 13% “weak” or “fair”.
This meant that needle exchange services were generally
providing a full range of harm reduction interventions, as well as
giving out injecting equipment. This was confirmed by the
interviews where almost all achieved the maximum score and all
of them could point to a wide range of harm reduction
interventions being delivered from their specialist harm reduction
services. Often their pharmacy needle exchange services were
able to deliver a range of harm reduction interventions as well. For
more information on the range of harm reduction services
delivered see section 4.2.3. For further information on the
services offered in pharmacy needle exchanges, see section
4.3.4.
4.3.4 Services offered to pharmacy 
needle exchange clients?
The review showed that the majority of partnerships were
performing well on this question, with the vast majority (86%)
scoring “excellent” or “good”. The interviewed areas performed
well on this issue, again almost all scoring four, and pointed to the
following issues relating to their pharmacy-based harm reduction
services.
Pharmacy participation in needle exchange schemes
Most of the partnerships interviewed reported a good
participation from pharmacies in pharmacy needle exchange
schemes and coverage of the whole local drug partnership area
had been made possible by a spread of these services. The
partnerships had taken a strategic view as to where the
pharmacy services were located, so that if a particular part of the
borough or county was identified as having poorer access, more
effort was made to recruit pharmacies to offer a needle exchange
service in that locality. The majority of pharmacies that took part
in supervised consumption schemes also offered needle
exchange, although usually more pharmacies in a given area
provided supervised consumption than needle exchange
services.
There were differences in the numbers of pharmacies involved in
needle exchange schemes, but the number of pharmacies
involved was not the important factor, because geographical area
and population size varied and all the partnerships interviewed
believed that they had good coverage of their area though a
combination of pharmacy and specialist needle exchange
services. Only a small number of partnerships felt that they
needed more pharmacy services to maximise coverage. Some
areas reported that they had not always had good coverage, and
as a result had made a concerted effort to recruit more
pharmacies to the scheme. 
Equipment distributed
All pharmacies gave out packs of needles and syringes (and
usually a sharps bin), although some also retained a small stock
of individual needles and syringes to give to clients as extra if
required. Some also gave out packs of other injecting equipment
(citric acid, Stericups and filters). In all areas interviewed,
pharmacists were paid by the number of packs given out.
Signposting to drug treatment services
All partnerships interviewed thought that it was important that all
pharmacy staff (pharmacists and counter staff) working with drug
users had at least a good working knowledge of the local drug
treatment system and were able to refer clients to appropriate
specialist harm reduction and drug treatment services. More
formal links between pharmacies and specialist harm reduction
and drug treatment services had been established in many areas,
such as drugs workers providing interventions in pharmacies.
Where necessary, training was provided to build pharmacy staff
knowledge and understanding about local services and the
mechanisms for referring clients (see also section 4.5.3). Some
areas had produced service directories or signposting documents
with information on local harm reduction and drug treatment
services that could be easily used by pharmacy staff to refer
clients.
Specialist harm reduction interventions in pharmacies
Some areas had drugs workers providing brief harm reduction
interventions in pharmacies and a few other areas intended to
make this type of service available in the near future. These brief
interventions – such as providing basic advice and information,
safer injecting and overdose advice, and even healthcare
assessments – were thought to be important in assisting
pharmacy staff by providing more specialist help to clients, and
offering the opportunity of a one-to-one session in private if
required.
Case study: Kensington and Chelsea peer-run needle
exchange
The Kensington and Chelsea peer-run needle exchange
started after a need was identified through a weekend user-
run social club, based at one of the local voluntary sector
treatment services. The user group running the social club
was regularly asked about the availability of needle exchange
facilities and as a result the user group worked with the
treatment service to open the existing needle exchange on
Saturday and Sunday afternoons. During these times, the
needle exchange is run by members of the user group who
have been trained in needle exchange assessments. The
service now acts as a first point of contact for many people
who are not in the local treatment system.
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Specialist drug interventions would normally require a private
consulting room in the pharmacy where the client could see a
practitioner. The partnerships reported that not all their
pharmacies had this facility, but most partnerships aspired to
having private rooms in all their pharmacies where physically
possible. One partnership would not accept pharmacies to be
part of their supervised consumption scheme unless they had a
private area, although this was not a requirement for needle
exchange. 
4.3.5 Hepatitis B vaccination and testing
This was one of the poorest-scoring questions in the review with
96 per cent of partnerships scoring “fair” or “weak”. Despite most
of the interviewed partnerships scoring two (two scored four),
they held the issue as high importance. They pointed to the
following issues, which they considered to be important in
providing a good blood-borne virus service to clients:
Blood-borne virus testing and vaccination
All partnerships interviewed placed a high priority on testing for
blood-borne viruses, with most reporting that they aim to test as
many drug users as possible. As far as they were able, drug
services offered tests for hepatitis B and C to all clients entering
harm reduction or drug treatment services. In some services, they
also offered tests for hepatitis A, HIV, or sexually transmitted
infections if appropriate or required. Most of the services
interviewed reported trying to make sure that blood-borne virus
issues were raised by staff at the client’s first assessment, or as
soon as possible afterwards.
Most services reported offering pre-test counselling before clients
took tests, which would be carried out by harm reduction nurses
or drugs workers. For the actual testing, partnerships reported a
mixture of oral swab testing and blood testing for hepatitis. Some
areas used swab testing in order to enable easier testing and to
test as many clients as possible. Other areas preferred blood
tests because of greater accuracy and because in most cases,
blood tests would have to be done to confirm the results of swab
tests anyway. If the first test was positive, the client would need
to get a PCR test. Most partnerships used local hospital labs for
test analysis.
All areas reported providing post-test counselling. If the test was
negative, the client would receive post-test counselling. If the test
was positive, the client would also receive post-test counselling
and would be referred to the nearest hepatitis C treatment clinic,
which was usually at the local hospital.
Most partnerships reported offering hepatitis A and B
vaccinations to clients in drug services. Some also reported
offering tetanus. Vaccinations were usually done by nurses in the
specialist harm reduction or substance misuse service, but
sometimes the vaccination would be done in primary care
services. The usual reported practice was to offer three types of
hepatitis B vaccinations depending on the client’s assessed risk
of disengaging with the programme of vaccinations. The options
were the regular, rapid and the accelerated programmes. The
rapid or accelerated programmes were offered to clients who
were assessed as possibly having difficulties completing the
regular programme.
4.3.6 Partnership responses to hepatitis C and HIV 
This was the question which showed the poorest performance in
the whole review, with almost all (98%) partnerships scoring “fair”
or “weak” and none scoring “excellent”. The issue of good
hepatitis C pathways was one that even the highly rated
partnerships interviewed admitted they struggled with, with all
scoring one and none reporting that they had a fully satisfactory
pathway. However, it was an issue that many of them had put a
lot of work into, and they were in the process of developing more
robust responses to hepatitis C locally, which included the
following aspects. 
Hepatitis C treatment
Hepatitis C treatment pathways for drug misusers were
established in most of the areas interviewed, however this was an
area that all partnerships felt could be improved. Some
partnerships were more confident than others about the quality
and robustness of the process and the hepatitis treatment the
clients were receiving, and many felt they still had a lot of work to
do in this area. 
The partnerships reported that a crucial component in hepatitis C
treatment for drug users was the relationship between the drug
treatment services and the hepatologist or other doctors running
the local hepatitis treatment services. Most partnerships reported
a good relationship with these clinicians with the specialist
hepatitis doctors generally favourably disposed towards the client
group. A few areas had worked hard to establish or improve this
relationship and had been successful in doing so. However, even
when there was a good relationship with the clinician, the
partnerships reported that there could still be issues with clients
actually getting the necessary hepatitis C treatment, mainly
because of waiting lists for treatment, or lack of accessibility of
the hepatitis clinic.
In most areas, it was the hepatologist who made the decision
whether to treat a particular patient. This was reported to be a
particular issue for patients who were still injecting drugs or
drinking heavily. It was also reported in a few areas that people
would sometimes be excluded from hepatitis treatment because
their drinking or drug use were deemed to be incompatible with
the interferon treatment. This practice is not consistent with the
NICE guidelines on treatment for hepatitis C (NICE, 2004; 2006)
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However, some partnerships pointed out that clients sometimes
excluded themselves from hepatitis treatment. In most areas it
was reported that even when some clients tested positive for
hepatitis C, they did not want to take up the treatment. It was
generally agreed that the issue of hepatitis C-positive clients
continuing to inject is something to be taken up in keyworking
relationships, where the client could be encouraged to stop
injecting or drinking alcohol.
Ensuring compliance with hepatitis C treatment
Some partnerships noted that there was often a problem with
clients not attending appointments at the hospital for hepatitis C
treatment. This was particularly a problem when the client had to
travel a long distance to reach the hospital, which was the case
in the majority of areas. Some services had put measures in
place to try to ensure attendance, the most common of which
was a “buddying” system where the client was accompanied to
their hepatitis treatment by a volunteer buddy. This system was
reported to generally work well, and encourage clients to attend
appointments. Other measures used to help clients keep
appointments included being accompanied by nurses or
keyworkers where they were able to spare the time to attend.
To maximise client engagement in hepatitis treatment, some
partnerships reported starting or being in the process of setting
up community-based hepatitis treatment services, for example a
system where after the initial hospital appointments, clients could
continue to receive their treatment in local community services,
administered by nurses.
Hepatitis support groups
Some areas had set up hepatitis support groups. Not all of these
were specifically for drug users with hepatitis C, though the
groups were felt to be of great benefit to all clients going through
hepatitis treatment, enabling them to discuss a range of issues,
including difficulties (such as depression) they were experiencing
with the treatment.
4.4 Criterion 9: Action to reduce drugrelated deaths
Results of the following questions are shown in Table 5.
1. Does the partnership have a written multi-agency strategic
plan for reducing drug-related deaths?
Case study: Nottinghamshire hepatitis treatment service
In Nottinghamshire county, hepatitis C treatment is provided in
the community for people who are not able to access the
secondary care treatment service. The Direct Access Harm
Reduction Service operates clinics running alongside existing
drug treatment clinics, needle exchanges and drop-ins to
maximise access. Clients are referred to the harm reduction
clinics for blood-borne virus interventions, including hepatitis B
and C testing, hepatitis B vaccination and referral to hepatitis
C treatment.
If a clients test positive for hepatitis C, they will receive a pack
with information about living well, reducing the risks of
transmission to families, hepatitis C treatment and what to
expect. The hepatitis C treatment service is delivered in a drug
treatment agency in the north of the county, and is nurse-led
with supervision provided by the consultant hepatologist.
Clients who would find it difficult attend hospital-based
hepatitis treatment will receive their hepatitis C treatment
there. 
Case study: Stockton buddying scheme
The local drug treatment service set up a buddying scheme to
help people through drug treatment. Initially set-up to be
delivered by a professional worker, once it was up and
running it was taken over by volunteers and the service users
themselves. It is a buddying scheme for drug treatment
generally, but it has a particular relevance for clients attending
hepatitis C treatment, who receive support and help in
attending appointments at the hospital in Middlesbrough.
Case study: Calderdale hep C support group
Calderdale has a peer-run hepatitis C support group. The
group was originally set up to be a stand-alone group, and it
has evolved over time. It is currently a support group for
people undergoing hepatitis C treatment with its own
constitution. The support to start up the group was provided
by a professional, but once established with a constitution it
became peer-run. The group is not exclusively for drug users,
but they make up the majority of the group. The focus of the
group tends to be on new diagnosis. The group is expected
to continue to evolve.
Q1 Q2 Q3 Q4
Weak 6% 22% 25% 10%
Fair 33% 3% 11% 23%
Good 37% 1% 3% 67%
Excellent 24% 74% 61% NA
Mean 2.8 3.3 3.0 2.6
Table 5: Responses to criterion 9 (action to reduce drugrelated
deaths)
18
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2. What proportion of paramedics in emergency ambulance
crews in the area have been trained in the use of naloxone?
3. What proportion of police custody officers have been trained
to deal with overdose incidents?
4. How many service users and carers have been trained
during 2005/06 to deal with overdose incidents?
The results showed that this was the strongest criteria and
nationally, partnerships had made significant progress in
developing systems and protocols to reduce the number of drug-
related deaths.
4.4.1 Strategic plans to reduce drug-related deaths
This issue scored reasonably in the review, with 61 per cent of
partnerships scoring “good” or “excellent”. However, this was still
an area for improvement in many areas with a third or
partnerships scoring only “fair”.
Most of the partnerships interviewed had a strategy for reducing
drug-related deaths, with almost all scoring highly for this
question. Usually, the drug-related deaths strategy was included
as part of the harm reduction strategy, rather than as a separate
document. This strategy was developed in the same way as the
harm reduction and other local partnership strategies using a
combination of data analysis and expert groups and implemented
and monitored through specific groups, often specifically focusing
on drug-related deaths. Some partnerships had joined up with
neighbouring partnerships to form groups with a wider strategic
focus on drug-related deaths.
4.4.2 Naloxone training for paramedics
This question was scored reasonably well across partnerships,
with three-quarters (75%) scoring “good” or “excellent”.
The interviewed partnerships all scored the maximum for this
question and reported that their local ambulance services carried
naloxone and paramedics were trained in its use. Naloxone
training for ambulance crews was carried out within the
ambulance service. None of the areas interviewed had made
take-home naloxone available to service users or carers, but
some were interested in investigating this further. 
4.4.3 Overdose training for police custody officers 
Almost two-thirds of partnerships (61%) scored “excellent” on the
issue of police custody officers being trained to deal with
overdose. The interviewed partnerships mostly scored four.
This training took place in different ways in the interviewed
partnerships. Usually, it was a multi-agency initiative, with police
receiving training from local partners such as drug treatment and
harm reduction service providers. This was reported to work best
when there were good partnership arrangements in place
between drug treatment and criminal justice agencies. In other
areas, the training was done in-house by the police force.
4.4.4 Overdose training for users and carers
Two thirds of partnerships (67%), including all of the partnerships
interviewed for this report, achieved the maximum score on
service users and carers being trained to deal with incidents of
overdose. 
All of the high-scoring partnerships interviewed provided training
for users and carers that addressed issues of overdose. These
training courses were commissioned by the partnership in
consultation with local user groups and forums and delivered in a
variety of ways across the local treatment system. Some courses
were held in neutral non-treatment venues if the local drug
services knew that this would improve attendance. In other areas,
the training was held in local treatment services because of
relative ease of access and familiarity. The courses were delivered
by a mix of local service providers; the ambulance service,
contracted trainers, and service users themselves, depending on
the particularly identified local needs.
4.4.5 Other relevant action on drug-related deaths
As well as the above areas under scrutiny in the service review,
the interviewed partnerships pointed to a number of other issues
that they believed were important in tackling drug-related deaths
locally. 
Confidential enquiry processes
Some, though not all, areas had established a confidential enquiry
process for drug-related deaths and other areas were in the
process of developing them. These processes varied, but usually
involved a nominated partnership lead on drug-related deaths
and an expert group. The drug-related deaths lead would usually
be the person who would liaise with the coroner’s office and
obtain information on local deaths. 
The main function of these processes was reported to be the
investigation of local drug-related deaths and identify any
appropriate lessons that could be learnt. The expert groups were
either set up specifically for these investigations, or were groups
that operated within existing local clinical governance structures.
The groups included representatives from relevant local bodies,
such as the partnership, drug services, the PCT, public health
and social services. Drug-related deaths would usually be
reported thorough the nominated lead and the group would look
at each death to examine the surrounding circumstances around
it and identify any recurring trends and patterns. These groups
were normally responsible for the production of reports on drug
related deaths, which were made available through local strategic
groups and actioned as appropriate.
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Relationships with local coroners
An important factor in all enquiries into drug-related deaths was
reported to be the relationship or links with the local coroner’s
office. Most areas had good links with coroners and were able to
work with them to access relevant information and participate in
enquiries. Other areas, however, had a more difficult relationship
with the coroner and were not able to access relevant
information. Added difficulties sometimes arose because coroners
usually cover more than one local drug partnership area. 
The nature of partnerships’ relationship with coroners was an
issue that varied widely according to the interviewed partnerships.
However, some partnerships had worked hard to build up a
better relationships and had been successful. 
One of the main issues that arose was how drug-related deaths
were recorded and what level of detail was given in coroners’
reports. There was no sense of any consistency across the
partnerships in how deaths were recorded and this was viewed
to be an ongoing issue.
Working with people leaving prison
All partnerships reported that reducing the overdose risk facing
people leaving prison and residential treatment was a major issue
in tackling the incidence of drug-related deaths. Most of the areas
had processes in place to ensure that people leaving prison had
rapid access to treatment services if required, Some of these
schemes included:
• Pick-up at the prison gate: the prisoner being released would
be met at the prison gate and accompanied to a drug
service. This would be done with the client’s consent in
partnership with DIP and the CARAT teams
• Ensuring that a triage assessment was already done before
the client left prison, enabling an appointment with a doctor in
the community to be set up in advance 
• Having available slots in substance misuse clinicians’
timetables at particular times to allow people newly released
from prison to have immediate access to treatment
Proactive work and drug-related deaths campaigns
Many areas reported that they had done proactive work on drug-
related deaths, which mostly meant specific targeted campaigns
to their service users about risks of death. This included raising
awareness and providing information and advice on safer
injecting and overdose as part of regular keyworking and times
when the client was at more risk of overdose, such as after
leaving prison, detoxification or residential rehabilitation.
Ambulance protocols
Most areas had developed a protocol between the local police
and ambulance service where the police would not routinely
attend a 999 call which was for a drugs overdose. This was felt
to have encouraged drug users to call 999 when a friend
overdosed, without the fear of arrest.
4.5 Criterion 10: Staff competences
The results of these questions are shown in Table 6.
1. Are there protocols in place to ensure staff safety in relation
to blood-borne viruses?
2. What training and experience in harm reduction do staff in
non-pharmacy fixed-based needle and syringe exchange
have?
3. What training and support is provided for pharmacy staff
providing needle exchange services?
4. Do service users feel respected by pharmacy staff?
5. What is the level of training or experience in harm reduction
amongst staff working in specialist community prescribing
services?
4.5.1 Protecting staff from blood-borne virus exposure
This was an issue that scored reasonably well in the service
review with over half (52%) of partnerships scoring “excellent”.
The interviewed partnerships mostly achieved the maximum
score.
Case study: Stockton enquiry process
To assist with the confidential inquiry process in Stockton, a
nominated post was created in conjunction with three other
Teeside partnerships (Middlesbrough, Hartlepool and Redcar
& Cleveland). This person is the nominated co-ordinator for
drug-related deaths across the four partnerships. This post
provides the crucial link with coroner’s office and is supported
by public health.
There is a cross-partnership drug-related deaths group
including representation from the local drugs partnership,
police, mental health, public health, probation and social
services. Information from the coroner comes back to this
group. The co-ordinator is informed of drug-related deaths
and then informs the rest of the group. The co-ordinator will
obtain relevant information from local services which have had
contact with the person who had died. 
The group has a monthly meeting, whether a death has
occurred or not. If there is no immediate death to investigate,
the group will review previous cases.
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4.5.2 Staff competency in non-
pharmacy needle exchanges
This was another area which scored reasonably well in the review
with over two-thirds (71%) of partnerships scoring “excellent” or
“good”. In the partnerships interviewed for this report, all scored
highly and all put a strong emphasis on the importance of training
their local treatment staff in harm reduction. Harm reduction
training was generally delivered across local drug treatment
systems, not by providing separate training for staff working in
needle exchanges and those working in drug treatment services
(see section 4.5.5 for information on treatment system-wide
training). However, it is worth noting that some partnerships
confirmed that staff working in more specialist harm reduction
services, or who had contact with more chaotic drug users,
received more in-depth training than colleagues who were
working with more stable clients.
4.5.3 Training and support for pharmacy staff 
providing needle exchange
Training and support for pharmacy staff providing needle
exchange services was an area which scored well in the review,
with well over three-quarters (81%) of partnerships scoring
“excellent” or “good”, a much higher score than for training for
staff working in specialist harm reduction services and drug
treatment services.
All the partnerships interviewed performed well on this question
(almost all scored four) and reported putting a strong emphasis
on ensuring that staff working with drug users in pharmacy
needle exchange services were adequately trained in harm
reduction and working with drug users. This applied to pharmacy
counter staff as well as the pharmacists. To meet ongoing training
needs, most areas had a rolling training programme for
pharmacists and counter staff.
It was felt important by partnerships that all new pharmacists
coming onto the needle exchange scheme receive training. The
training input began when the pharmacies first started providing
needle exchange services. Some areas provided resources for
pharmacies new to the scheme. One area had set up a 24-hour
helpline to assist pharmacists with drugs issues.
In most partnerships, pharmacists dispensing prescriptions to
drug users were required to have some kind of certification.
Some partnerships insisted that the lead pharmacist had a
certificate from the Royal Pharmaceutical Society, and other areas
insisted that pharmacists involved in the needle exchange
scheme go through some sort of accredited training. Often this
was Centre for Pharmacy Postgraduate Education (CPPE)
accredited training, but some areas in the north-west used the
Harmonisation of Accreditation Group (HAG) course, which is a
fully accredited rolling programme.
The training events were held at regular intervals with a variation
across the partnerships as to when and how they took place.
Some areas ran evening courses so the pharmacists and other
staff did not have to take time out of work to attend. Other areas
ran courses during the day and these partnerships would usually
pay for locum cover while the pharmacists were in training
(sometimes this cost was covered by the PCT). In some areas,
pharmacists would receive payment for attending courses. It was
understood that these training courses for pharmacy staff were
popular and well attended. Some partnerships had recognised
the need for training locum pharmacists in harm reduction and
were taking steps to meet this particular need.
In many areas, these training courses involved staff input from
local specialist drug treatment and harm reduction services. This
also helped to create good links between the pharmacies and the
drug services. Service users’ input was also part of many of the
training courses.
Q1 Q2 Q3 Q4 Q5
Weak 6% 13% 17% 30% 17%
Fair 37% 16% 3% 28% 26%
Good 5% 59% 26% 40% 43%
Excellent 52% 12% 55% 1% 14%
Mean 3.0 2.7 3.2 2.1 2.5
Table 6: Responses to criterion 10 (staff competencies)
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4.5.4 Respect from pharmacy staff
This was an issue that did not generally perform well in the
service review with over half (58%) of partnerships scoring “fair”
or “poor”. This may have been due to poor training of pharmacy
staff in working with drug-using clients. Only one of the
partnerships interviewed scored four and the rest showed a
mixed picture. Some of these areas reported that pharmacy staff
attitudes to service users had been a problem in one or more of
their pharmacy services, but often this was reported to the
partnership through user consultation mechanisms and they were
able to deal with problems by liaising with the relevant
pharmacies and providing training where necessary.
4.5.5 Harm reduction training in specialist 
community prescribing services
This issue scored adequately in the service review, with just over
half (57%) of partnerships scoring “excellent” or “good”. The
interviewed partnerships again displayed a mixed picture, with
scores ranging from one to four.
Staff competence in providing harm reduction across the local
drug treatment system was an important issue for all partnerships
interviewed. It was standard practice for all substance misuse
staff to receive some harm reduction training. Many partnerships
also pointed to the importance of harm reduction training for the
wider group of health, social care and criminal justice staff
working with drug users. 
Regular harm reduction training for drug service staff working with
drug users was provided across all of the partnership areas,
funded by the joint commissioning group. Examples of this
included:
• Comprehensive harm reduction training, provided by in-house
by experienced staff or by external training providers
• Blood-borne virus training, sometimes specifically focusing on
particular viruses
• Overdose and overdose prevention training delivered in-house
or sometimes by ambulance staff
• Safer injecting training
• Updates to previously received harm reduction training 
• Harm reduction training for police dealing with drug users
custody suites, as well as non-police staff working in custody
suites
• Harm reduction training for other non-drug specialist staff
working with drug users, such as housing, probation and
other Tier 1 healthcare staff.
The training was usually provided based in identified training
needs and commissioned by the partnership, and delivered in a
variety of ways including in-house training for larger agencies and
multi-agency training across a range of local treatment providers,
or other professionals working with drug users. Often there was a
specific minimum level of training provided, for example a specific
number of days for each staff member.
Some areas had created a specific post that was responsible to
co-ordination of local training, including working with services to
identify training needs, organising the delivery of the training,
contracting with training providers where necessary and delivering
training courses.
Some areas pointed to consistency of staffing as an important
factor in good performance in harm reduction. Treatment staff
who were in place for a long time in services were believed to
have had the opportunity to build up longer-term relationships
with the clients as well as with other people in partner agencies.
There was also a case made for consistency in staffing at the
centre of the local drug partnership contributing to good
performance in the service review.
4.6 Other contributory factors
In addition to the issues that correspond to the criteria and
questions used in the service review, there were some other
issues which were raised in the interviews, which were thought to
be relevant to the partnership’s good performance on harm
reduction. 
Case study: Tameside pharmacy training
Tameside requires all of their pharmacists and pharmacy
counter staff to go through the accredited HAG
(Harmonisation of Accreditation Group) course. The HAG is a
task group to harmonise specific enhanced service
accreditation and competence requirements for community
pharmacies within the north west. Tameside works with HAG
and other local drug partnerships on the accreditation of
pharmacists across Greater Manchester. This accreditation is
not substance misuse specific, but there is a harm reduction
component. This course provides substance misuse training
with a focus on harm reduction. 
The course is fully evaluated and run as a rolling programme.
Staff from the specialist drug services also attend this course
in order to improve relationships and links between specialist
services and pharmacists. 
Pharmacists are trained on areas including working with the
client group, injecting techniques and injecting equipment. The
service user group is involved in the training, which is believed
to be helpful because pharmacists can receive direct input
from the service users and have some of their questions
answered, and the service users are able to see the training
pharmacists receive and better understand the pressures
faced by pharmacy staff.
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4.6.1 Co-ordinated harm reduction services
All of the partnerships interviewed employed people in co-
ordination roles to oversee and run the local harm reduction
services, but these roles varied from area to area. In most places,
the specialist harm reduction services and the pharmacy needle
exchange services were separate and few areas had a single
needle exchange or harm reduction co-ordinator who oversaw
the whole local system (specialist and pharmacy services).
However, all of the interviewed areas had a co-ordinator for the
pharmacy exchange system. The nature of this post varied
across partnerships and was the responsibility of a range of staff
such as harm reduction nurses, drugs workers and people
whose specific role was to co-ordinate the local pharmacy
system. Most of these co-ordinators were employed by the
statutory drug service or PCT, but there were examples of the co-
ordinator being part of the local voluntary sector community
service.
The needle exchange co-ordinator 
All areas had a specific post for the co-ordination of pharmacy
needle exchange. This person had a range of responsibilities,
depending on the area, but usually included the following:
• Dealing with stock and equipment supply to pharmacist – the
co-ordinator would visit pharmacies regularly to deliver packs
and other equipment
• Collecting needle exchange activity data which would be
used to decide payments and to monitor clients in the
pharmacy system and fed into local harm reduction
databases
• Dealing with queries from the pharmacies
• Recruitment of new pharmacies and maintaining relationships
with pharmacies already in the scheme
• Providing training and ongoing support to pharmacists – this
involved making regular visits to pharmacies to discuss staff
training needs. One area had a separate needle exchange
mentor to assist pharmacists and staff with harm reduction
issues
• Delivering one-to-one training interventions with pharmacy
staff
• Liaison across pharmacies, specialist treatment providers and
service users
• Meeting with local pharmaceutical committee representatives
• Delivering opportunistic one-to-one harm reduction
interventions with service users in pharmacies, if the co-
ordinator was competent to do this.
4.6.2 Distribution and return of injecting equipment
Ensuring widespread distribution 
There was a division among the interviewed partnerships on
policies for the distribution and return of injecting equipment.
Some areas had an expressed intention to give out as much
equipment as possible, regardless of the number of returns, to
ensure that injectors has as much access to clean equipment as
possible in order to reduce the potential for contracting blood-
borne viruses.
Secondary distribution
This was another issue that showed differences between high-
performing partnerships. Some services actively encouraged
secondary distribution in the quest to get as much clean injecting
equipment as possible out to drug users. Other areas did not
encourage this practice, mainly because they were uncomfortable
with the idea that people might be using injecting equipment
without any advice or information on how to use it correctly or
safely. The areas that encouraged secondary distribution reported
that they utilised peer education and training, where a number of
service users were trained in safer injecting who could then
educate their peers in safer injecting.
Encouraging returns
Generally, the return rates of injecting equipment reported were
fairly high, with some areas reporting return rates as high as 95–
100 per cent. Some partnerships had run campaigns to
encourage returns. Although campaigns were found to be
effective, there was a stronger emphasis on the relationship
between staff in harm reduction services (including pharmacy
staff) and the service users, as being important in encouraging
returns. Through these relationships with clients, the staff usually
found it possible to discuss issues relating to discards and the
importance of safe disposal and returning used works. If there
were problems in getting returns from some clients, staff often
would emphasise how discarded needles can have a negative
effect on the needle exchange service’s reputation and thus
threaten the future availability of the service. One area had done
presentations on injecting equipment found in particular areas to
bring the issue closer to home to service users, especially since
these were often the areas where the clients lived. It was also felt
useful to have thank you messages on posters and other material
to encourage users who were returning equipment, to continue to
do so.
Dealing with drug litter
There were differences between partnerships on whether
discarded injecting equipment was a problem or not. In many
areas, it was reported as not being significant. In other areas
there were more drug litter issues, but the partnership and
services had been able to identify particular hotspots and take
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appropriate action. In both types of area, there were usually good
links with the local authorities through the environmental health
and waste management department. 
For the areas that had problems with discarded needles, a
number of ways of tackling this were used. 
• One area had a 24-hour helpline where community members
could inform the DAT about discards and raise other
concerns
• User involvement in collecting discards – one area had a team
of trained service users who collected discarded sharps. This
kind of involvement raised awareness among other users and
had helped to bring down discards overall through a form of
peer pressure
• Direct work with users through relationships and discussions
– one area used images of discards to bring the reality of the
problem home to service users
• Placing of secure public sharps bins in hotspot areas to
enable easier returns. In one area, this included a sharps bin
in a hospital that had been identified as having a problem with
discards
• One area had set up a specific drug litter group involving
environmental health
• In some areas, local community wardens and park wardens
were trained in disposal of injecting equipment
• Active attempts by service users to deal with the problem of
discards were found to help with local attitudes towards drug
users. To promote this, one partnership did a survey with
local shopkeepers; an exercise which in itself also helped to
improve relationships.
4.6.3 Harm reduction in non-drug treatment settings
There were discussions about a variety of different harm
reduction interventions in non-drug treatment settings. The most
common of these were harm reduction interventions provided by
criminal justice workers in police custody suites (see also section
4.4.3). All interviewed partnerships had services that provided
some advice, information and referral to people held in custody
for drug-related offences. This included talking to clients about
issues such as blood-borne viruses, safer injection and making
them aware of services in the community. A small number of
areas had a needle exchange in the policy custody suite. 
Other examples of harm reduction services in non-drug treatment
settings included:
• Harm reduction workers in magistrates’ courts
• Providing harm reduction training to housing staff
• Training community wardens in harm reduction
• A hospital pharmacy running a needle exchange
• Needle exchange in a hospital A&E
• Needle exchange in hostels.
5 Conclusion
The NTA and Healthcare Commission harm reduction
improvement service review found evidence of good practice in
harm reduction services, but also that many improvements can
still be made, even for these scoring highly overall. This overall
finding was reflected in the areas selected for interview. 
The interviews revealed that even in the partnerships that are
performing well, there are still a few areas for improvement. A
number of these were highlighted in most interviews and included
harm reduction for stimulant users, testing for blood-borne
viruses, and particularly treatment pathways for hepatitis C. 
However, although it was a necessarily limited interview sample,
there was plenty evidence of good, innovative practice and
robust strategic service development. The harm reduction
practices of these areas are therefore worth considering and have
been set out in the report with the aim of providing useful pointers
for other areas. Partnerships that also performed well on harm
reduction may not find anything particularly new in this report but
it is the NTA’s experience, in this and past reviews, that
partnerships that scored less highly will usually have a something
to learn from the areas that are performing well. The practice
highlighted by the interviewed partnerships provides a basis for
building good-quality harm reduction services.
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7 Appendix 1: Key documents 
and guidance
7.1 Models of Care: Update 2006
Models of Care for the treatment of adult drug misusers is the
national framework for the commissioning and provision of drug
treatment services in England. Although the NTA had already
stressed the importance of harm reduction in the original Models
of Care for the treatment of adult drug users (NTA, 2002), the
2006 update of Models of Care (NTA, 2006a) had a specific aim
of a greater emphasis in harm reduction as a core component of
all structured treatment interventions (Tiers 1–4). One of the main
reasons for this was the reported rises in blood-borne viruses and
site infections among injecting drug users and an increase in
drug-related deaths.
7.2 Clinical guidelines
Drug Misuse and Dependence: UK Guidelines on Clinical
Management (DH et al., 2007) is the national clinical guidelines for
clinicians providing pharmacological interventions for drug
misusers as a component of drug misuse treatment. It was fully
updated and published in September 2007 and this update fully
replaces the original 1999 clinical guidelines.
The 2007 clinical guidelines provide guidance on the treatment of
drug misuse in the UK. They are based on current evidence and
professional consensus on how to provide drug treatment for the
majority of patients, in most instances.
The updated clinical guidelines cover harm reduction in chapter
six. There are extensive sections on both blood-borne infections –
covering prevention and testing, responding to exposure to
infection, and a range of viral infections and bacterial infections –
and preventing drug-relating deaths, covering causes of drug-
related deaths, how clinicians can reduce these deaths in their
patients and how to deal with overdose.
7.3 Reducing DrugRelated Harm: An Action Plan
This plan was published by the Department of Health in May
2007 to set out the broad streams of action to be taken in
England to enhance harm reduction activities within drug
treatment services. The aim of the plan is to limit to number of
drug misusers dying from drug-related causes or contracting
blood-borne virus infections.
The action plan builds on previous work on reducing drug-related
harm and reflects lessons drawn from an expert group. It sets out
all the activities to be undertaken within the each of the three
strands, which are:
• Campaigns
• Improving delivery
• Increased surveillance.
7.4 Hepatitis C Action Plan
The growing importance of hepatitis C as a public health issue
was highlighted in 2002 with the publication of the Government’s
Hepatitis C Strategy for England. It brought together existing
initiatives to tackle hepatitis C and suggested how prevention,
diagnosis and treatment could be improved. The Hepatitis C
Action Plan, published by the Department of Health in 2004, is
based on best practice, serves as a broad framework for
implementation of the Hepatitis C Strategy for England. It reflects
ongoing work that needs to be sustained and intensified and also
identifies new areas for action.
Since the publication of this action plan, the Health Protection
Agency has subsequently published yearly updates describing
progress on the plan. There have been three Hepatitis C Strategy
for England reports to date.
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7.5 NICE guidance on needle exchange and syringe
programmes
NICE is currently in the process of developing public health
intervention guidance on the optimal provision of needle
exchange schemes among injecting drug users. This guidance
will provide recommendations for good practice, based on the
best available evidence of effectiveness, including cost
effectiveness. The scope of this guidance has been consulted on
and the final scope was published in January 2008. Consultation
on this guidance will take place throughout 2008, with the final
guidance expected in February 2009.
7.6 Shooting Up reports
The Health Protection Agency has been producing Shooting Up,
a yearly update focusing solely on infections among injecting drug
users in the United Kingdom, since 2002. The reports focus on
the current prevalence of the main viral infections (hepatitis A, B,
C and HIV) and bacterial infections (staphylococcus aureus
infections, group A streptococcal infections and clostridial
infections) as well as making recommendations.
The key findings of the latest Shooting Up report (2007) include:
• Injecting into the groin and the injection of crack cocaine,
which are both associated with higher levels of infection and
injecting risk, have become more common
• Overall hepatitis C infection among injecting drug users has
increased in recent years, with almost half now infected.
• The level of HIV infection in England and Wales among
injecting drug users has increased since the start of the
decade to one in 75.
• There has been a marked increase in the number of injecting
drug users receiving the hepatitis B vaccine, with two-thirds
now reporting vaccination.
7.7 The Safer Injecting Briefing
The Safer Injecting Briefing (DrugScope, 1999) is produced as a
guide to promoting safer injecting. The guidance covers areas
such as the evidence base for promoting safer injecting, routes of
administration, vein damage, transmission of blood-borne viruses
and providing comprehensive services to tackle unsafe injecting
practices.
7.8 NICE hepatitis C guidance
The National Institute for Health and Clinical Excellence (NICE)
has produced a number of guidance reports on hepatitis C. The
guidance most currently relevant is the 2004 technology appraisal
(TA) 75 Interferon alfa (pegylated and non-pegylated) and ribavirin
for the treatment of chronic hepatitis C. This guidance notes that
although current injecting drug users can have high rates of
discontinuation of hepatitis C treatment in trials, there is evidence
that where adherence is achieved, success rates are not
significantly different. The rate of discontinuation of hepatitis C
treatment by injecting drug users in trials would not be so great
as to prevent the treatment being cost effective.
Technology appraisal guidance 106 Peginterferon alfa and
ribavirin for the treatment of mild chronic hepatitis C was
published in August 2006, as an extension of the guidance given
in TA75.
8 Appendix 2: Partnerships 
involved and rationale
8.1 Partnerships interviewed
The following partnerships were interviewed about their harm
reduction practice: Nottinghamshire, Kirklees, Bradford, Harrow,
Stockton-on-Tees, Tameside, Knowsley, Calderdale, Wigan,
Brent, Kensington & Chelsea, Cheshire
8.2 Rationale for selection
The partnerships highlighted above were selected by an iterative
process to specifically identify those partnerships which scored
highly on harm reduction. The rationale was that a partnership
might be particularly good at either harm reduction or
commissioning but less good at the other. Therefore rather than
merely select the partnerships with the highest overall score, a
number of checks were applied to the review data.
The selection process looked at the scores for each criterion
within commissioning and harm reduction, and the scores for the
questions which made up the criteria. We noted the partnerships
that scored consistently well across a range of criteria, those that
scored well across the questions within particular criteria and
those that scored badly for any particular criteria. 
These criteria were looked at individually. The partnerships which
scored the highest possible score (14-16) for harm reduction
were identified in tables.
The three highest-scoring partnerships (scoring 16) were
immediately selected for interview. Since there was not enough
time or resources to interview all partnerships which scored 14–
16, an iterative process was used to determine which
partnerships to interview. This involved looking in more detail at
their scores for individual criteria and questions which make up
the criteria.
The four harm reduction criteria were looked at individually. The
partnerships which had the highest overall score for each of the
criteria were identified. A number of other factors were also
considered for each partnership. These were:
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• The number of times where individual partnerships achieved
the maximum score across for all the criteria
• The criteria for which the partnership scored the highest
aggregate score (if any). This is based on the tables in
appendix 1
• The total and overall improvement review scores – this shows
if the partnership was in among the top scoring partnerships
across the whole improvement review. Only partnerships
scoring four overall are considered here
Applying these factors helped to narrow down a smaller number
of partnerships to prioritise for contacting. The partnerships that
were selected are those that have achieved the maximum score
for individual criteria consistently, have scored well on all the
questions within particular criteria, or have scored highly overall in
the service review. 
9 Appendix 3: Themes from 
the National Conference on
Injecting Drug Use
To augment the interviews of partnerships that scored highly on
harm reduction in the 2006/07 NTA/Healthcare Commission
improvement review, some informal consultation was carried out
at the National Conference on Injecting Drug Use in Glasgow
(NCIDU) on 15 and 16 October 2007. This consultation consisted
mainly of discussions that took place in a room set aside during
the conference breaks and at a meeting of the National Needle
Exchange Forum on 15 October.
Given that the NTA was in the process of interviewing local drug
partnerships which were scored as being good at harm
reduction, the consultation question asked to participants was:
“What are the five key elements that you would expect to see in
an area that is good at harm reduction?”
The responses covered the following themes.
9.1 Diversity of service provision
• “More than just needles”
• Harm reduction provided in as many different ways as
possible. (specialist services, pharmacy, outreach, mobile
needle exchanges etc)
• Full range of injecting equipment available in needle
exchanges
• Give out injecting equipment in large volumes.
• Good service provision for steroid users
• Ability of reach black and minority ethnic groups with harm
reduction services
9.2 Good access to harm reduction services
• Comprehensive coverage of harm reduction services in local
areas
• Good out-of-hours access, including the use of 100-hour
pharmacies
• Wider availability of needle exchange through pharmacies 
• Outreach services actively finding people and targeting hard
to reach groups.
• More home delivery services
• Clear referral routes in place between pharmacy and specialist
services, with awareness that some clients may only attend
pharmacy service, and who may need to be encouraged into
other services
9.3 Good quality bloodborne virus interventions
• Screening and anonymous testing of blood-borne viruses
(hepatitis B and C and HIV) as widely as possible
• Providing as hepatitis B vaccinations to all service users
• Clear routes into treatment for hepatitis C, to make it easier
for clients to access treatment 
9.4 Good access to harm reduction nurses
• More nurses in needle exchange service to carry out
healthcare interventions
• More nurse-led harm reduction drop-in clinics
• Nurses providing general healthcare assessments to clients.
9.5 Good links with structured drug treatment
There would be good links between drug treatment and harm
reduction services. Examples given of what these links might look
like included: 
• Shared skills and experience between Tier 2 and 3 services
• Harm reduction through treatment services.
9.6 User involvement
• Good user consultation and participation in harm reduction
service
• Overdose training provided for users and concerned others
• Availability of peer-based harm reduction workshops,
including peer training on overdose.
9.7 Staff competence
• Staff trained in blood-borne viruses and able to raise sexual
health issues
Good practice in harm reduction
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• Good quality staff training on harm reduction, which ideally
would involve users 
• Ideally, harm reduction training would be mandatory for
everyone involved in working with drug users, including
pharmacy shop and counter staff
• Training including pre and post-hepatitis test discussions
• Good signposting between pharmacy needle exchange,
specialist needle exchange and other services. 
9.8 Strategic
• Partnerships and services need to have a good
understanding of the needs of the client group
• Good “partnership buy-in” enabling the harm reduction
system to work properly
• Good co-ordination of harm reduction services done by a
competent professional
• Having good links between the partnership, health promotion
and public health.
10 Appendix 4: Service review
partnership rankings
The tables on the following pages show the partnerships ranked
by their overall harm reduction score from the service review, and
the scores from the four harm reduction criteria. There is further
data from the review on the NTA website www.nta.nhs.uk
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Partnership Criterion 7 Criterion 8 Criterion 9 Criterion 10
Overall harm
reduction score
Bradford 4 4 4 4 16
Brent 4 4 4 4 16
Stockton-on-Tees 4 4 4 4 16
Bolton 4 3 4 4 15
City of London 4 3 4 4 15
Darlington 4 3 4 4 15
Ealing 4 3 4 4 15
Kensington and Chelsea 4 4 4 3 15
Knowsley 4 3 4 4 15
Liverpool 4 3 4 4 15
Oldham 4 3 4 4 15
Solihull 4 4 4 3 15
Southend-on-Sea 4 3 4 4 15
Southwark 4 3 4 4 15
Thurrock 4 3 4 4 15
Wigan 4 3 4 4 15
Cheshire 4 3 4 3 14
Croydon 4 3 4 3 14
Hammersmith and Fulham 4 3 4 3 14
Harrow 3 3 4 4 14
Kirklees 4 3 4 3 14
Lancashire 4 3 4 3 14
Middlesbrough 4 3 4 3 14
Newcastle upon Tyne 3 3 4 4 14
North East Lincolnshire 4 3 4 3 14
Nottinghamshire 4 3 4 3 14
Oxfordshire 4 3 4 3 14
Southampton 3 4 4 3 14
Tameside 3 3 4 4 14
Torbay 3 4 4 3 14
Tower Hamlets 3 3 4 4 14
Walsall 4 3 4 3 14
Wirral 4 3 4 3 14
Blackpool 4 2 4 4 14
Calderdale 4 2 4 4 14
County Durham 4 2 4 4 14
Manchester 4 4 4 2 14
West Berkshire 4 2 4 4 14
Birmingham 3 3 4 3 13
Bournemouth 3 3 4 3 13
Dorset 3 3 4 3 13
Islington 4 3 3 3 13
Kingston Upon Hull 3 3 4 3 13
Lambeth 3 3 4 3 13
Leeds 3 3 4 3 13
Service review partnership rankings
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Partnership Criterion 7 Criterion 8 Criterion 9 Criterion 10
Overall harm
reduction score
Rotherham 3 3 4 3 13
Salford 3 3 3 4 13
Sunderland 3 3 4 3 13
Westminster 3 3 4 3 13
Bristol 4 3 4 2 13
Buckinghamshire 4 2 4 3 13
Bury 4 2 4 3 13
Devon 4 3 4 2 13
Essex 4 2 4 3 13
Gateshead 4 3 4 2 13
Haringey 4 2 3 4 13
Luton 4 2 4 3 13
Northumberland 4 3 4 2 13
Poole 4 3 4 2 13
Reading 4 2 4 3 13
Sefton 4 2 4 3 13
Sheffield 3 4 4 2 13
Trafford 3 2 4 4 13
Wandsworth 4 2 4 3 13
Norfolk 3 3 3 3 12
Barnet 4 2 3 3 12
Bexley 2 3 4 3 12
Cornwall & Isles of Scilly 2 3 4 3 12
Doncaster 4 2 3 3 12
Gloucestershire 2 4 3 3 12
Greenwich 3 3 2 4 12
Leicester 3 3 4 2 12
Lewisham 3 2 4 3 12
Lincolnshire 3 3 4 2 12
North Lincolnshire 3 3 4 2 12
Rutland 3 2 4 3 12
Somerset 3 2 4 3 12
Stockport 3 2 4 3 12
Waltham Forest 3 3 4 2 12
Warwickshire 3 2 4 3 12
Wolverhampton 3 2 4 3 12
South Gloucestershire 4 2 4 2 12
Barking and Dagenham 3 3 3 2 11
Brighton and Hove 3 2 3 3 11
Hillingdon 2 3 3 3 11
Newham 3 3 2 3 11
North Tyneside 2 3 3 3 11
Sandwell 3 2 3 3 11
Swindon 3 3 2 3 11
Blackburn with Darwen 2 2 4 3 11
Service review partnership rankings
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Partnership Criterion 7 Criterion 8 Criterion 9 Criterion 10
Overall harm
reduction score
Bracknell Forest 3 2 4 2 11
Cambridgeshire 4 2 3 2 11
Coventry 2 3 2 4 11
Cumbria 2 2 4 3 11
Derbyshire 2 2 4 3 11
Dudley 3 2 2 4 11
Hackney 2 2 4 3 11
Halton 3 2 4 2 11
Hartlepool 2 2 4 3 11
Leicestershire 3 2 4 2 11
Plymouth 2 2 4 3 11
Rochdale 2 2 4 3 11
Shropshire 2 3 4 2 11
Stoke-on-Trent 2 3 4 2 11
Windsor and Maidenhead 2 2 4 3 11
Barnsley 2 3 3 2 10
Derby 2 2 3 3 10
East Sussex 3 2 2 3 10
Hampshire 3 2 2 3 10
Hertfordshire 3 2 2 3 10
Kingston upon Thames 2 2 3 3 10
Nottingham 2 3 3 2 10
Portsmouth 3 2 3 2 10
South Tyneside 3 2 3 2 10
St Helens 2 3 2 3 10
Suffolk 3 2 3 2 10
Sutton 3 3 2 2 10
Telford and Wrekin 2 3 2 3 10
Wakefield 3 2 3 2 10
Wokingham 3 2 2 3 10
York 2 2 3 3 10
East Riding of Yorkshire 2 2 4 2 10
Enfield 2 2 2 4 10
Havering 2 2 4 2 10
Isle of Wight 2 2 4 2 10
Slough 2 2 4 2 10
Bath and North East Somerset 3 2 2 2 9
Bedfordshire 2 2 2 3 9
Bromley 2 2 3 2 9
Herefordshire 2 2 3 2 9
Kent 2 2 2 3 9
Merton 2 2 2 3 9
North Somerset 2 2 2 3 9
North Yorkshire 2 2 3 2 9
Northamptonshire 2 2 2 3 9
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Partnership Criterion 7 Criterion 8 Criterion 9 Criterion 10
Overall harm
reduction score
Staffordshire 3 2 2 2 9
Warrington 2 2 2 3 9
Wiltshire 2 2 3 2 9
Hounslow 2 2 1 4 9
Camden 2 2 2 2 8
Medway towns 2 2 2 2 8
Redbridge 2 2 2 2 8
Surrey 2 2 2 2 8
Worcestershire 2 2 2 2 8
Milton Keynes 2 2 1 3 8
Peterborough 1 3 2 2 8
Redcar and Cleveland 2 1 3 2 8
West Sussex 2 2 1 3 8
Richmond upon Thames 1 2 2 2 7
Service review partnership rankings
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